Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used primarily for the treatment of major depressive disorder, generalized anxiety disorder, and certain types of pain such as neuropathic pain and fibromyalgia. It works by inhibiting the reuptake of both serotonin and norepinephrine in the central nervous system, thereby increasing their levels and enhancing neurotransmission[1][5][8]. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) indicated for major depressive disorder and generalized anxiety disorder. It selectively inhibits the serotonin transporter (SERT), leading to increased synaptic concentrations of serotonin. Escitalopram also binds to an allosteric site on SERT, which may further modulate its activity[6]. Both drugs are prescription antidepressants with established efficacy in depression and anxiety disorders; duloxetine has broader FDA-approved uses including pain syndromes, while escitalopram is noted for its high selectivity for SERT and generally favorable tolerability profile[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on duloxetine vs. escitalopram.